ETHACRYNATE SODIUM FOR INJECTION POWDER FOR SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

ETHACRYNIC ACID (ETHACRYNATE SODIUM)

थमां उपलब्ध:

ENDO PAR INNOVATION COMPANY, LLC

ए.टी.सी कोड:

C03CC01

INN (इंटरनेशनल नाम):

ETACRYNIC ACID

डोज़:

50MG

फार्मास्यूटिकल फॉर्म:

POWDER FOR SOLUTION

रचना:

ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

50ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

LOOP DIURETICS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0101703001; AHFS:

प्राधिकरण का दर्जा:

CANCELLED PRE MARKET

प्राधिकरण की तारीख:

2023-07-07

उत्पाद विशेषताएं

                                PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
ETHACRYNATE SODIUM FOR INJECTION
House Std.
_ _
Lyophilized powder for injection, 50 mg equivalent to ethacrynic
acid
Intravenous
Saluretic-Diuretic Agent
Endo Par Innovation Company, LLC
6 Ram Ridge Road, Chestnut Ridge,
New York 10977, USA
Imported/Distributed by:
Paladin Labs Inc.
100 Alexis Nihon Blvd., Suite 600
Saint-Laurent, Quebec, Canada
H4M 2P2
Date of Preparation:
July 30, 2018
Version 1.0
Submission Control No: 209656
_Product Monograph_
_Page 2 of 20_
_Ethacrynate Sodium for Injection_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
......................................................................................................
5
WARNINGS AND PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
......................................................................................................
7
DRUG INTERACTIONS
......................................................................................................
8
DOSAGE AND ADMINISTRATION
..................................................................................
9
OVERDOSAGE
...................................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 10
STORAGE AND STABILITY
............................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..........................................................................
11
DOSAGE FORMS, COMPOSITION AND
PACKAGING................................................ 11
PART
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 30-07-2018

इस उत्पाद से संबंधित अलर्ट देखें